Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    3TREES Sees Asia-Pacific Cooperation as a Win-Win Business Boost

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026
    Oran Star: Algeria’s news. Maghreb perspective.Oran Star: Algeria’s news. Maghreb perspective.
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Oran Star: Algeria’s news. Maghreb perspective.Oran Star: Algeria’s news. Maghreb perspective.
    Home » Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance
    Featured News

    Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance

    July 30, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Shares of Danish pharmaceutical company Novo Nordisk fell sharply by 20% on Tuesday after the company cut its full-year sales and profit outlook and named a new chief executive officer. The market reaction came amid ongoing challenges in the U.S. market for the company’s widely used obesity and diabetes drugs.

    Novo Nordisk now expects full-year 2025 sales growth of 8% to 14%, down from its previous projection of 13% to 21%. Operating profit growth is expected to range between 10% and 16%, also lower than the prior estimate of 16% to 24%. The company cited slower-than-anticipated sales of its weight-loss drug Wegovy and diabetes treatment Ozempic in the second half of the year as key drivers of the revised outlook.

    The company also announced that Maziar Mike Doustdar will take over as president and CEO, effective August 7. A Novo Nordisk veteran since 1992, Doustdar most recently served as executive vice president for international operations. His appointment follows the unexpected departure of Lars Fruergaard Jørgensen, whose removal was announced in May after a prolonged decline in the company’s stock performance.

    Wegovy and Ozempic sales pressure second-half performance

    Despite reporting a 40% increase in second-quarter operating profit and an 18% rise in sales year-on-year, Novo Nordisk warned of slower momentum for the remainder of the year. It noted that compounded GLP-1 drugs continue to impact demand for Wegovy in the U.S., even after the expiration of a temporary exemption granted by the U.S. Food and Drug Administration (FDA) earlier in 2025.

    Competition in the weight-loss drug market has also intensified. Prescriptions for rival Eli Lilly’s weight-loss drug Zepbound surpassed those of Wegovy in March. In addition, Novo Nordisk has faced negative sentiment following disappointing clinical trial results for its next-generation obesity candidate, CagriSema.

    Stock price falls over 50 percent year-to-date

    The company is actively pursuing legal and regulatory strategies to combat the impact of unauthorized compounded drugs in the U.S. market. Executives have indicated that they expect availability of copycat drugs to decline in the second half of the year, but uncertainty remains regarding the pace of recovery in U.S. sales. Novo Nordisk’s stock has declined more than 50% over the past year.

    Tuesday’s selloff erased significant gains made during the prior year’s Ozempic-driven rally, which had briefly made Novo Nordisk the most valuable listed company in Europe. Analysts say investors will be watching closely for the company’s full second-quarter earnings report, scheduled for release on August 6, as well as updates on its product pipeline and regulatory developments. – By Eurowire News Desk.

    Related Posts

    International Ombudsman Forum Establishes Worldwide Independent Defender Union (WIDU)

    November 19, 2026

    Clemta Expands Partner API to Power End-to-End U.S. Business Services

    November 12, 2026

    Finshape launches Agentic DBOS: agentic AI for digital banking, already live in several bank projects

    November 5, 2026

    ARE YOU READY FOR THE BIGGEST IIFA EVER?

    November 5, 2026

    Luma Ventures and KII Formalise Strategic Cooperation to Build the Infrastructure for Kurdistan’s Future Economy

    October 28, 2026

    Integrated Identity Unveils Proprietary Global Media Infrastructure

    October 22, 2026
    Current News

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026
    © 2026 Oran Star | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.